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Activation of 6-Globin Gene Expression by Erythroid Krupple-Like Factor: 
A Potential Approach for Gene Therapy of Sickle Cell Disease 
By David Donze, Paxson H. Jeancake, and Tim M. Townes 
Hemoglobin A2 (HbA2; aa2) is a powerful inhibitor of HbS 
(a&;) polymerization. However, HbA2 levels are normally 
low in sickle cell patients. We show that a major reason for 
low 6-globin gene expression is the defective CACCC box at 
-90 in the &globin promoter. When the CACCC box defect 
in S is corrected, expression of an HS2 NLuciferase reporter 
is equivalent to HS2 /?/Luciferase. Erythroid Krupple-like fac- 
tor (EKLF), which binds to the CACCC box of the /?-globin 
gene and activates high-level expression, does not bind to 
the normal 6-globin promoter. Our goal is to design a modi- 
fied EKLF that binds to the defective &globin promoter and 
enhances &-globin gene expression. To test the feasibility of 
this strategy, we inserted the /?-globin CACCC box at -90 
of the 6-globin gene promoter to produce an HS2 SCAC-p 
construct and quantitated human 6- and /?-globin mRNA in 
stably transformed murine erythroleukemia (MEL) cells. 6- 
URRENT GENE THERAPY strategies for sickle cell C disease focus on transduction of hematopoietic stem 
cells with viral vectors containing antisickling globin genes.’-4 
Although this is a viable approach, expression of therapeutic 
levels of 0-globin mRNA and protein from transduced genes 
may be difficult to achieve (Palmer et a1: Weatherall: 
McCune et al,’ and M. Sadelain, personal communication, 
June 1996). An alternative approach is to transduce stem 
cells with a transcription factor gene encoding a protein that 
specifically enhances endogenous &globin gene expression. 
In this case, relatively low levels of a novel transcription 
factor may stimulate high levels of 6-globin gene expression. 
Hemoglobin A2 (HbA2; a2&) is a powerful inhibitor of 
HbS (a&) polymerization*; however, HbA2 levels are low 
in most sickle cell patients and in normal individuals (2% 
to 3% of total Hb).9 One reason for low &globin expression 
is the defective CACCC box at -90 in the 6-globin gene 
promoter (see below); this region is known to be important 
for P-globin gene expression.1°-12 The major CACCC box- 
binding protein in the adult @-globin gene is the erythroid- 
specific, zinc finger transcription factor EKLF (Erythroid 
Krupple-like factor).13 This protein binds to the 0-globin 
CACCC box and, in conjunction with proteins bound to 
locus control region (LCR) sequences, activates high-level 
P-globin gene expre~sion.’~.’~ Our goal is to design a modi- 
fied EKLF that binds specifically to the defective S-globin 
gene promoter and enhances S-globin gene expression. The 
results described below show the potential of this approach 
and suggest that modified EKLF proteins could be used in 
gene therapy strategies to enhance HbA2 synthesis and in- 
hibit erythrocyte sickling. 
MATERIALS AND METHODS 
Plasmid constructions. The construction of plasmid HS2 @Lucifer- 
ase has been described.14 The plasmid contains the 1.5-kb Kpn I-Bgl 
II human LCR HS2 fragment upstream of the -265 to +48 human p- 
promoter driving the Luciferase reporter gene of plasmid pGL2-Basic 
(Promega Corp, Madison, WI). HS2 6Luciferase was constructed by 
polymerase chain reaction (PCR) amplification of the -265 to +48 
region of the &promoter with Bgl II ends attached to the primers. The 
template used was a human globin locus subclone containing the entire 
&gene, and the primer sequences (Bgl II sites underlined) were as 
Globin mRNA in these cells was 22.0% ? 9.0% of total human 
globin mRNA (6/6 + p)  as compared with 3.0% f 1.3% in 
the HS2 6-/? control. In a second set of experiments a GAL4 
DNA-binding site was inserted at -90 of the S-globin gene 
to produce an HS2 6GAu-/? construct. This construct and a 
GAL4,,.,,,,/EKLF expression vector were stably transfected 
into MEL cells. &Globin mRNA in these cells was 27.8% 5 
7.1% of total human globin mRNA as compared with 9.9% ? 
2.546 in the HS2 6GAw-p plus GAL4,,.147, control. These results 
show that 6-globin gene expression can be significantly in- 
creased by a modified EKLF. Based on these results, we sug- 
gest that modified EKLFs, which contain zinc fingers de- 
signed to bind specifically to the defective 6-globin CACCC 
box, may be useful in gene therapy approaches to increase 
HbA2 levels and inhibit HbS polymerization. 
0 1996 by The American Society of Hematology. 
 follow^: upstream, 5’-CTCGAGGCTAGCAGATCTGAAAAATG- 
AAACTAGA-3‘; and downstream, 5’-CTC-TAGCAGATCT- 
CTGWGAGGTTGCTAGTGA-3‘. The PCR product wasdigested 
with Bgl I1 and cloned into the plasmid HS2nuc.” Modified FA‘-’ 
and S A c . 2  promoters were made by the megaprimer mutagenesis 
method,’*-*’ using the same outside oligos listed above with the follow- 
ing mutagenic oligos: FA‘-‘, 5’-TITTCA’ITCTCACAAACTAAC- 
CACACCCTGCITATC’ITAAACCA-3’; 5’-TCATITlTC- 
The consensus EKLF-binding sites are in bold, and these fragments 
were cloned into HS2iLuc as above. 
To construct the HS2 6-p gene plasmids, the 3.0-kb Xba I-Sph I 
fragment of the &globin gene (from -400 to about 1 kb downstream 
of the poly A site) was first subcloned into pUC19. The modified 
6-promoters (amplified from the -400 Xba I site to the Sal I site at 
- 13) were then synthesized by megaprimer mutagenesis using the 
same mutagenic oligos listed above and the outside primers 5 ’ -  
AGTTTAAACTGCAGCAATAG-3’ (starting at -460 of the b-pro- 
moter) and 5’-CTTCTCCTCAGGAGTCAG-3’ Gust downstream of 
the translation start). These PCR fragments were cut with Xba I and 
Sal I and were used to replace the corresponding wild-type fragment 
in the &gene pUC 19 subclone. The GFA”-promoter was constructed 
in the same fashion, using the mutagenic oligo 5’-GAAGGTTCATT- 
TITCATTCTCCGGAGGACAGTCCTCCGG CTTATCTTAA- 
ACCAACCTGC-3’, with the consensus GAL4-binding site” in 
bold. Each of these &genes was cut out of the pUC19 vector with 
Xba I and HindIII, blunted with S 1 nuclease, and cloned into plasmid 
AlTCTCACAAACCACACCCTCCCECITATCITAAACCAA- 3’. 
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Fig Comparison of the human 6- and 8-promoters and modification of the &promoter to contain EKLF-binding sites. [A) The p-globin 
locus on human chromosome 11. (6) The p -  and 6-globin promoters were aligned using the GAP program of the GCGIWiaconsin package; 
only the regions of interest are shown. The consensus EKLF-binding site in the p-globin promoter (CCACACCCT) is located at bases -85 to 
-93 from the transcription start site, and this sequence is underlined. The wild-type &globin promoter region has a partial EKLF-binding site 
IACCCT) at bases -81 to -85. To create the modified timc.’ promoter, site-directed mutagenesis was used to convert the partial site to a 
consensus EKLF-binding site. The SCAc’ promoter contains the EKLF-binding site at basas -85 to -93; this is the same distance from the 
transcriptional start site as is the p-globin promoter EKLF-binding site 
5‘HS2(K-P)p?* which was cut with Cla I and S1-blunted. All PCR- 
amplified regions in each of these constructs were completely veri- 
fied by dideoxy sequencing using the Sequenase kit (US Biochemi- 
cals Corp, Cleveland, OH). 
The pCIneo-GAL4,1.14,,/EKLF plasmid was constructed in two 
steps: A 0.8-kb Nco I-Msl I cDNA fragment containing the coding 
sequence (amino acids 2-275) of the murine EKLF activation domain 
(from plasmid pSG5-EKLF)” was blunted with SI nuclease and 
cloned in-frame into the GAL4 DNA-binding domain expression 
plasmid pBXGl (gift from M. Ptashne, Harvard University, Cam- 
bridge, MA). The pBXGlEKLF plasmid was cut with HindIII and 
BamHI, and the 1.3-kb GAL4~I.147,/EKLF fragment was isolated, 
S I-nuclease-blunted, and cloned into pCIneo (Promega Corp) cut 
with Sma I. As a control, the 0.5-kb GAL4-binding domain HindIII- 
BamHI fragment from pBXGl was cloned into pCIneo as above 
[pCIneo-GALA, 
MEL cells 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% fetal bovine serum (FBS). For transient transfec- 
tions, cells were washed once and resuspended to IO* cells/mL in 
RPMI-1640 media without serum. For transient luciferase assays, 
40 pg of HS2 promoter/Luciferase plasmids were mixed with 5 pg 
internal control plasmid CMV-0 gal (Clontech Lab, Palo Alto, CA) 
in 100 pL phosphate-buffered saline and were placed in a 0.4-cm 
gap electroporation cuvette (Bio-Rad, Hercules, CA). MEL cells (5 
x lo7) in 0.5 mL RPMI-1640 media (without serum) were added 
to each cuvette, and cells were electroporated at 260 V and 960 pF 
in a Bio-Rad Gene Pulser. The contents of each cuvette were trans- 
ferred into a 100-mm plate containing 10 mL DMEM/10% FBS and 
were incubated for 8 hours. After 8 hours, dimethyl sulfoxide 
(DMSO) was added to 1.65% to induce erythroid differentiation. 
This 8-hour preincubation before DMSO induction increased cell 
viability and gene expression levels severalfold when compared with 
Murine erythroleukemia (MEL) cell transfections. 
those of cells induced immediately after electroporation. Cultures 
were incubated for 3 days, and then cell extracts were assayed for 
luciferase and 0-galactosidase as de~cr ibed .~ . ’~  Transient transfec- 
tions were performed 3 times in triplicate. 
Transfection of MEL cells to produce (3418-resistant populations 
was performed essentially as described by Collis et al.” A total of 
20 pg of HS2 6-0 plasmids (with 6, tjCAC-I, or 6CAC2 promoters) 
was mixed with a 1: 10 molar ratio of plasmid pgk-neo (the murine 
phosphoglycerate kinase promoter driving neomycin phosphotrans- 
ferase; a gift from R. Mortensen, Harvard University). Both plasmids 
were linearized with Kpn I, precipitated, and dissolved in 100 pL 
phosphate-buffered saline. The plasmid mix was placed into a 0.4- 
cm electroporation cuvette, and 2 x IO7 MEL cells (prepared as 
above) in 0.5 mL RPMI-1640 media were added. Cells were electro- 
porated at 200 V and 960 pF and were transferred to 30 mL DMEM/ 
10% FBS in a 75-cm2 culture flask. After 48 hours, (3418 was added 
to a final concentration of 300 pg/mL, and resistant cell populations 
were selected for 2 weeks. Cells were then induced with 1.65% 
DMSO for 3 days, and total RNA was extracted as described.” The 
HS2 SGAL4-D experiments were performed as above, using a I : 10 
molar ratio of the pCIneo plasmids, which were linearized with Xmn 
1. 
The relative 
levels of 6- to 0-globin transcripts were determined by the single 
nucleotide primer extension (SNuPE) assay, which is based on de- 
tecting single known nucleotide differences in allelic 
Briefly, RNA from MEL cells transfected with HS2 6-0 constructs 
was amplified by reverse transcription-PCR (cDNA cycle kit; 
Invitrogen, San Diego, CA) using oligo dT to prime the cDNA 
reaction. The PCR primers were as follows: upstream, 5‘-TGlTCA- 
CTAGCAACCTCAAAC-3’; and downstream, 5’-TGAAGlTCT- 
CAGGATCCACGT-3’. There are no differences in 6- and &globin 
sequences in these regions, and the primers do not amplify mouse 
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6-globin promoter (data not shown). To test the feasibility 
of using a modified EKLF to activate &globin gene expres- 
sion, we determined whether a &globin promoter containing 
a P-globin EKLF-binding site would increase expression by 
recruiting endogenous cellular EKLF in transient transfec- 
tion assays. We replaced the defective EKLF-binding site in 
the 6-globin promoter (TGAAACCCT from -89 to -81; 
see Fig 1) with the consensus CCACACCCT to construct 
the plasmid HS2 SCAC-'/Luciferase. We also constructed a 
modified 6-globin promoter that contained the CCACAC- 
CCT sequence at -93 to -85, so that the EKLF site would 
be positioned the same distance from the transcription start 
site as it is in the ,&globin promoter (HS2 SCAC%uciferase). 
Figure 2 shows the relative expression levels of these 
modified 6-promoterLuciferase reporter constructs when 
linked to an LCR HS2 fragment and transiently transfected 
into MEL cells. In this assay, HS2 6Luc was expressed at 
10% of the level of HS2 @/Luc. When the consensus EKLF 
site was placed in the 6-globin promoter at the -81 to -89 
site (HS2 SCAC-'/Luc), expression was increased approxi- 
mately fivefold, to 56% of HS2 OLuc expression. HS2 
/Luc, with the consensus EKLF site at -85 to -93, 
expressed the reporter gene at 99% of HS2 p/Luc. These 
results show that the major defect of the 6-globin gene proxi- 
mal promoter is the lack of a consensus EKLF-binding site. 
In addition to promoter defects, low 6-globin expression 
has been attributed to other differences between the 6- and 
P-globin genes. The 6-gene lacks intragenic enhancers that 
augment @-globin e x p r e ~ s i o n ~ ~ ~ ~ '  and &globin mRNA is less 
stable than P-globin To assess the effects of these 
differences on SCAC-' and 6CAC-2 expression, we constructed 
complete &globin genes (see Materials and Methods) con- 
taining the 6, liCAC I ,  and 6CAC-Z promoters (Fig 3A). These 
&globin genes were used to produce HS2 6-p constructs. 
The plasmids were then cotransfected into MEL cells with 
a pgk-neo selectable marker, and G4 18-resistant populations 
were selected. After differentiation was induced with 
DMSO, RNA was extracted and the relative levels of 6- and 
@-globin mRNAs were determined by the SNuPE assay.25 
Table 1 shows the results of these experiments. The level of 
&globin mRNA (6/6 + p) in MEL cells was 3.0% 5 1.3% 
for HS2 6-p, 14.9% 5 7.4% for HS2 6'*' '-0, and 22.0% 
? 9.0% for HS2 6CAC-2-p. These results show that the inser- 
tion of a consensus EKLF-binding site in the 6-globin pro- 
moter significantly enhances &globin gene expression in a 
construct that contains the entire 6-globin gene. A represen- 
tative example of the SNuPE assay is shown in Fig 3B; 6/6 
+ P-globin mRNA in this experiment was 3.6% for HS2 6- 
0, 24.7% for HS2 6'".'-p, and 34.8% for HS2 6cAc-2-b. As
a control, 6- and P-globin mRNA levels were determined 
for human reticulocyte RNA (Fig 3B); the 6/6 + /? level was 
0.6% ? 0.2%. 
These results suggest that EKLF binding to the &globin 
gene promoter significantly stimulates expression; however, 
the experiments do not exclude the possibility that other 
CACCC-binding factors are responsible for this increase. To 
confirm that the EKLF activation domain can enhance 6- 
globin gene expression, we constructed an HS2 gGAL4-/? plas- 
mid in which the consensus GAIA-binding site replaced 
sequences from -80 to -99 of the 6-globin gene promoter 
6CAC-2 
A .  
p, 8, or GCAC 
H S 2  promoter r, Luciferase 
K p n  I B g l  I 1  - 2 6 5  + 4 8  
B .  
- I T  T 
Fig 2. Transient expression of HS2 6-promoterlLuciferase plas- 
mids in MEL cells. (A) Schematic diagram of &globin promoterlre- 
potter plasmids. The 1.5-kb Kpn I-BglII LCR HS2 fragment was linked 
to the -285 to +48 wild-type P-, 6-, and modified 6-globin promoters 
described in Fig 1. These promoters were used to drive luciferase 
repotter gene expression in transiently transfected MEL cells. Lucifer- 
ase activity was normalized to P-galactosidase expression from an 
internal control CMV-P-galactosidase plasmid. (BI HS2 BlLuc expres- 
sion was normalized to 100%. Inclusion of the consensus EKLF site 
into the Sac' and 6-'-* promoters increased HS2 6lLuc expression 
from 10% to 56% and 99% of HS2 PILuc, respectively. 
globin mRNAs (data not shown). These oligos specifically amplify 
the corresponding 341-bp fragments of both the human 6- and P- 
globin cDNAs, and the fragments were purified by agarose gel elec- 
trophoresis. The detection oligo, 5'-C'ITCTCCTCAGGAGTCAG- 
3', hybridizes to the identical sense strand sequence of both 6- and 
P-globin cDNA PCR products (corresponding to nucleotides +77 
to +60 of each message) and is extended to base +59 by a3'P- 
deoxyadenosine triphosphate in the 6 reaction or by c~~~P-deoxygua- 
nosine triphosphate for the P reaction. Labeled products were re- 
solved on a 15% polyacrylamide/8 m o m  urea gel, and bands were 
quantitated on a Molecular Dynamics Model 425 Phosphorimager 
(Molecular Dynamics, Sunnyvale, CA). Linearity of the assay was 
verified as describedz5 by mixing experiments using RNA from MEL 
cells transfected with either HS2 P or HS2 P-promoterl6-gene as 
sources containing the individual messages (data not shown). 
RESULTS 
The 6- and P-globin genes are located at the 3' end of the 
P-globin locus on human chromosome 11 (Fig 1A). Compar- 
ison of the 6- and @-globin proximal promoters (Fig 1B) 
shows two key differences; the &globin promoter lacks con- 
sensus CACCC and CCAAT boxes, which are important for 
adult P-globin gene EKLF, which binds to 
the &globin CACCC box (CCACACCCT)" from bases -93 
to -85 of the promoter, is critical for P-globin gene expres- 
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%6 3.6 24.7 34.8 0.5 
Fig 3. Expression of modified S-globin genes in MEL cells stably transfected with HS2 S-p constructs. (A) Schematic diagram of HS2 6-0 
construct. The parental HS2 6-p  construct contained a 1.9-kb Kpn I-Pvu II HS2 fragment, a 3.0-kb R-globin gene beginning at base -400 from 
the transcription start site, and a 4.1-kb p-globin gene beginning at base -815 from the transcription start site. The corresponding ScAc" and 
modifications were inserted t o  create HS2 RcAc.'-p and HS2 SCAC-'-p. These constructs were transfected into MEL cells with a pgk-neo- 
selectable marker, and G418-resistant populations were selected. The cells were induced to  differentiate with DMSO, and RNA was extracted 
for analysis. (B) The relative levels of R- and p-globin mRNAs were determined by the SNuPE assay and quantitated by phosphorimager 
analysis. Inclusion of the consensus EKLF site into the ScAc.'- and SCAc.'-globin genes increased R-globin mRNA levels from 3.6% to  24.796 and 
34.8% of total S + p mRNA, respectively. 
fiCAC.2 
(Fig 4A). The coding sequence of the murine EKLF activa- 
tion domain (amino acids 2-275) was fused in-frame to the 
GAL4 DNA-binding domain (amino acids 1-147). and the 
fusion fragment was subcloned into the pCIneo expression 
vector (Fig 4B). MEL cells were cotransfected with HS2 
6""'.J-fi plus pClneo-GALA, 1.1.17, or HS2 6""'.'-fl plus pCI- 
neo-GAL4,1.1J7,/EKLF. Stable pools of G418-resistant cells 
Table 1. Relative Levels of &Globin Transcripts From MEL 
Transfections and Human Reticulocyte Samples as Percentages of 
Total Human b + 0 Transcripts 
HS2 6-0 HS2 bcAc '-0 HS2 b"c'-fl Reticulocyte 
Experiment no. 
1 3.6 24.7 34.8 0.5 
2 1.9 10.0 15.0 0.7 
3 1.6 5.8 12.3 0.8 
4 4.7 19.0 25.7 0.3 
Average 3.0 2 1.3 14.9 2 7.4 22.0 2 9.0 0.6 2 0.2 
Expression of modified b-globin genes in MEL cells stably trans- 
fected with HS2 6-0 constructs. These constructs were transfected 
into MEL cells with a pgk-neo-selectable marker, and G418-resistant 
populations were selected. The cells were induced to differentiate 
with DMSO, and RNA was extracted for analysis. The relative levels 
of b- and 0-globin mRNAs were determined by the SNuPE assay and 
quantitated by phosphorimager analysis. 
were selected, and, after DMSO induction. 6- and &globin 
mRNA levels were determined by the SNuPE assay de- 
scribed above. The data in Table 2 show that the level of 
human b/b + f i  mRNA is 9.9% 2 2.5% in cells containing 
HS2 6"""'-B plus ~ C I ~ ~ O - G A L ~ , , . ~ , ~ ,  and 27.8% 2 7.1% in  
cells containing HS2 6""'.'-p plus pCIneo-GAL4, 
EKLF. A representative example is shown in Fig 4C: the 
level of human 6/6 + p mRNA is 4.4% in cells containing 
HS2 6-8 plus pCIneo-GAL4,1.1J7). 13.3% in cells containing 
HS2 6""."-0 plus pClneo-GAL4,1.147,. and 36.6% in cells 
containing HS2 6""1-'-fi plus ~CI~I~~-GAL~,~.~~~,/EKLF. 
These results show that a modified EKLF can significantly 
increase &globin gene expression. 
The threefold increase (4.4% to 13.3%) of &globin gene 
expression observed when 6 promoter sequences from -80 
to -99 are replaced with a GAL4-binding site suggests that 
this region binds a factor that represses expression. A three- 
fold increase is also observed when the -80 to -99 region 
of the &globin promoter is deleted in an HS2 6-p globin 
construct. As discussed below, a modified EKLF that dis- 
places this and enhances b-globin gene expression 
will be designed. 
DISCUSSION 
Current gene therapy approaches for treatment of sickle 
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%6 4.4 13.3 36.6 
Fig 4. GAL4/EKLF activates &globin gene expression in an HS2 fiGAL4-p construct. (AI Schematic drawing of the reporter plasmid HS2 8'"- 
j3. This construct contains a consensus GALCbinding site (expanded) replacing &globin promoter bases -80 t o  -99. IB) pClneo effector 
constructs expressing either the GAL4 DNA-binding domain (amino acids 1-147) alone or GAL41,.1.71 fused t o  the EKLF activation domain (amino 
acids 2-2751. (C) HS2 ficAL'-j3 was stably transfected into MEL cells with either pClneo-GAL4,,.,,,, or ~ C ~ ~ ~ O - G A L ~ , , . ~ , ~ , / E K L F ,  and relative 
transcript levels were determined by the SNuPE assay. The level of human ti/& + fi  was 4.4% in cells containing HS2 6-fi, 13.3% in cells 
containing HS2 8GAL'-j3 plus pClneo-GAL4,,.,,,,, and 36.6% in cells containing HS2 fiGAL4-p plus ~C~~~O-GAL~,~.,,,,/EKLF. These results show that 
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Table 2. Relative Levels of &Globin Transcripts From MEL Cells 
Transfected With HS2-hGAL4-8 and GAL411.1d71 Expression Constructs 
as Percentages of Total b + 8 Transcripts 
HS2 hcAr '4  + HS2 hGAL'-p + 
GAL4,  1 w  G A L k  , d E K L F  
Experiment no. 
1 13.3 36.6 
2 8.4 30.2 
3 6.7 16.8 
4 11.3 27.3 
Average 9.9 2 2.5 27.8 i- 1.1 
GALUEKLF activates &globin gene expression in an HS2 bGAL4-/7 
construct. HS2 bGAL4-4 was stably transfected into MEL cells with 
either pClneo-GALO,, 1171 or pClneo-GAL4,, ,,,JEKLF, and relative tran- 
script levels were determined by the SNuPE assay. These results show 
that a modified EKLF can significantly increase b-globin gene expres- 
sion. 
cells with antisickling globin genes.'" Although this is a 
viable approach, expression of therapeutic levels of &globin 
mRNA and protein from transduced genes may be difficult 
to achieve (Palmer et a1,5 Weatherall." McCune et al,' and 
M. Sadelain, personal communication. June 1996). An alter- 
native approach is to transduce stem cells with a transcription 
factor gene that specifically enhances endogenous b-globin 
gene expression. In  this case. relatively low levels of a novel 
transcription factor may stimulate high levels of 6-globin 
gene expression. We propose that modified EKLFs, which 
contain zinc fingers designed to bind specifically to the de- 
fective b-globin CACCC box. may be used in genetic therapy 
approaches to increase HbA2 levels and to inhibit HbS poly- 
merization. The experiments in this report were performed 
to test the feasibility of this approach. 
The results presented here show that the ma.jor defect in  
the proximal b-promoter is the lack of a consensus EKLF- 
binding site. Insertion of an EKLF-binding site at -85 to 
-93 increased b promoter activity to levels equivalent to 
those of 0. Although other defects including the lack of 
intragenic enhancers'"'" and reduced b-globin mRNA stabil- 
ity"' inhibit &globin gene expression, correction of the 
CACCC defect resulted in b expression levels as high as 
34.8% of total b + 0 mRNA in constructs that contained 
complete 6- and @globin genes. The results of the GAL4/ 
EKLF experiments confirm that a modified EKLF can acti- 
vate b-globin gene expression to 36.6% of total b + o. HbA? 
( C Y & )  is ;I powerfiil inhibitor of HbS (a,!?:) polymerization: 
in vitro studies show that HbA, is as effective as HbF ( a 2 y 2 )  
at inhibiting the polymerization that causes erythrocyte sick- 
ling.s Platt et al" recently showed that HbF levels greater 
than 8.6% significantly enhance the survival of patients with 
sickle cell disease. Elevation of HbA, levels from the normal 
range of 2% to 3% to levels that are greater than 8.6% should 
similarly enhance survival. 
How can EKLF be modified to bind to the defective b- 
globin gene promoter and enhance expression? Recently. 
several groups have used the phage display system'' to select 
modified zinc-finger proteins that bind to novel sites.3''36 In 
an elegant set of experiments, Choo et al" showed that a 
modified Zif268 transcription factor, which was selected by 
phage display. could bind to the BCR-ABL translocation 
break point and inhibit BCR-ABL oncogene expression. The 
results show that zinc finger proteins can be functionally 
modified to exert a specific physiological effect. We are 
presently tising phage display to select EKLF variants that 
bind to wild-type b-globin promoter sequences with high 
affinity and specificity. These "b-EKLF" proteins will then 
be tested in MEL cells containing the HS2 6-0 construct to 
determine the level of b-globin gene activation. The results 
described above suggest that b-globin levels greater than 
8.6% of total b + mRNA may be possible. The model 
depicted in Fig 5 shows this effect. The efficacy of 6-EKLF 
EKLF \ 
LCR 
Fig 5. Model of "6-EKLF" activation of &-globin gene expression. The fi-globin gene is normally expressed at a low level in erythroid cells. 
One reason for low &globin expression is the defective CACCC box at -90 in the 6-globin gene promoter. We propose that a modified EKLF 
(6-EKLFI, which contains zinc fingers designed to bind specifically to the defective fi-globin CACCC box, may be used in genetic therapy 
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expression will be tested in transgenic animals containing 
the human 6- and ,@-globin genes and in hematopoietic stem 
cells obtained from sickle cell patients. 
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